GlassScriptPhysician profile
Scott D Pollack
NPI 1366633166
$64,203.29
in general payments reported to CMS, 2019-2025
35 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $21.80 · 2021: $404 · 2022: $997 · 2023: $2,781 · 2024: $39K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $12K · Travel and Lodging: $9,909 · Food and Beverage: $7,928 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,820.00 |
| Consulting Fee | $11,955.00 |
| Travel and Lodging | $9,908.84 |
| Food and Beverage | $7,928.07 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $40,361.65 | 2024-2025 | Voquezna |
| Laborie Medical Technologies Corp. | $12,478.18 | 2023-2025 | Alphaone |
| Medtronic, INC. | $3,279.11 | 2022-2025 | Gi Genius, Manoscan, Endoflip |
| Abbvie INC. | $2,146.70 | 2021-2025 | |
| Gastrogpo, LLC | $1,754.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $548.44 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $453.02 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $373.18 | 2021-2025 | Entyvio |
| Vital Connect, INC | $301.64 | 2022 | |
| Genzyme Corporation | $260.75 | 2022-2025 | |
| Celgene Corporation | $207.53 | 2021-2024 | Zeposia |
| Pfizer INC. | $193.21 | 2021-2025 | |
| Covidien LP | $177.74 | 2019-2020 | |
| Gilead Sciences, INC. | $169.45 | 2019-2025 | |
| Janssen Biotech, INC. | $157.89 | 2023-2025 | Stelara, Tremfya, Simponi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anx Robotica Corp | $156.35 | 2024 | |
| Sight Sciences, INC. | $150.70 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Celltrion USA INC. | $139.40 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $124.53 | 2024-2025 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $118.41 | 2024-2025 | Utaswako Afp-L3 |
| Ipsen Biopharmaceuticals, INC | $102.78 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $76.83 | 2022-2024 | Linzess |
| Boston Scientific Corporation | $66.51 | 2022-2024 | Exalt Model D |
| Merck Sharp & Dohme LLC | $59.87 | 2022-2024 | Dificid |
| Daiichi Sankyo INC. | $59.08 | 2024 | Injectafer |
| Lilly USA, LLC | $56.67 | 2024-2025 | Omvoh |
| Organon LLC | $43.51 | 2023-2025 | Hadlima |
| Aimmune Therapeutics, INC. | $37.61 | 2025 | Zenpep |
| Novo Nordisk INC | $36.50 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $32.55 | 2022-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $27.88 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $14.37 | 2023 | Terlivaz |
| Amgen INC. | $13.88 | 2023 | Avsola, Amjevita |
| Alnylam Pharmaceuticals INC. | $13.64 | 2025 | Givlaari |
| Micro-Tech Endoscopy USA, INC. | $9.73 | 2024 | Dat Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,889.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.